# Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection

> **NCT04357730** · PHASE2 · COMPLETED · sponsor: **Denver Health and Hospital Authority** · enrollment: 50 (actual)

## Conditions studied

- Severe Acute Respiratory Syndrome
- Respiratory Failure
- Acute Respiratory Distress Syndrome

## Interventions

- **DRUG:** Alteplase 50 MG [Activase]
- **DRUG:** Alteplase 50 MG [Activase]

## Key facts

- **NCT ID:** NCT04357730
- **Lead sponsor:** Denver Health and Hospital Authority
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-14
- **Primary completion:** 2021-03-21
- **Final completion:** 2021-09-30
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2022-01-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04357730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04357730, "Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04357730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*